Elagolix sodium

TypeName: Business Offer

Category:

Country: United States

Summary: Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma. Elagolix was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued.
https://www.bocsci.com/elagolix-sodium-cas-832720-36-2-item-354739.html

Description: [RequestDescription]

OfferId: 2403

Name:Alex Brown

Telphone:

Email:[email protected]

No Man

Elagolix sodium

Advertising